136 related articles for article (PubMed ID: 38744633)
1. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Catalano M; Santoni M; Roviello G
Eur Urol; 2024 May; ():. PubMed ID: 38744633
[No Abstract] [Full Text] [Related]
2. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
[TBL] [Abstract][Full Text] [Related]
3. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Kawahara T; Hasizume A; Uemura K; Yamaguchi K; Ito H; Takeshima T; Hasumi H; Teranishi JI; Ousaka K; Makiyama K; Uemura H
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686503
[TBL] [Abstract][Full Text] [Related]
4. A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
Future Oncol; 2024 Mar; 20(7):351-360. PubMed ID: 37994649
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
[TBL] [Abstract][Full Text] [Related]
6. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Hoimes CJ; Flaig TW; Milowsky MI; Friedlander TW; Bilen MA; Gupta S; Srinivas S; Merchan JR; McKay RR; Petrylak DP; Sasse C; Moreno BH; Yu Y; Carret AS; Rosenberg JE
J Clin Oncol; 2023 Jan; 41(1):22-31. PubMed ID: 36041086
[TBL] [Abstract][Full Text] [Related]
7. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
Azizi A; Houshyar R; Mar N
J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
[TBL] [Abstract][Full Text] [Related]
8. Durable Response After Combination Therapy With Enfortumab Vedotin and Radiotherapy in Metastatic Urothelial Carcinoma: A Report of Two Cases.
Ikarashi D; Kikuchi K; Takahashi K; Ariga H; Obara W
Cureus; 2023 Dec; 15(12):e49936. PubMed ID: 38179399
[TBL] [Abstract][Full Text] [Related]
9. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Chen DC; AlSaffar H; Graefen H; Perera S; Mazzone E; Perera ML; Lawrentschuk N; Murphy DG
Eur Urol; 2024 Apr; ():. PubMed ID: 38631993
[No Abstract] [Full Text] [Related]
10. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Klümper N; Vera-Badillo FE; Eckstein M; Hadaschik B; Grünwald V
Eur Urol; 2024 Apr; ():. PubMed ID: 38599990
[No Abstract] [Full Text] [Related]
11. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M; Nishimura N; Oda Y; Miyamoto T; Ohmori C; Takamatsu N; Itami Y; Tachibana A; Matsumoto Y; Kiba K; Tomioka A; Yamamoto H; Okajima E; Masaomi K; Sakamoto K; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
Jpn J Clin Oncol; 2024 Mar; 54(3):329-338. PubMed ID: 38061911
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of ATP-binding cassette transporters in enfortumab vedotin-resistant urothelial cancer.
Kotono M; Kijima T; Takada-Owada A; Okubo N; Kurashina R; Kokubun H; Uematsu T; Takei K; Ishida K; Kamai T
IJU Case Rep; 2024 Mar; 7(2):173-176. PubMed ID: 38440718
[TBL] [Abstract][Full Text] [Related]
13. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
[TBL] [Abstract][Full Text] [Related]
14. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
16. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.
Morikawa T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Iida K; Isobe T; Noda Y; Shimizu N; Aoki M; Gonda M; Banno R; Kubota H; Ando R; Umemoto Y; Kawai N; Yasui T
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730675
[TBL] [Abstract][Full Text] [Related]
17. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
19. Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
Taoka R; Kamada M; Izumi K; Tanimoto R; Daizumoto K; Hayashida Y; Uematsu K; Arai H; Sano T; Saito R; Hirama H; Kobayashi T; Honda T; Osaki Y; Abe Y; Naito H; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Ueda N; Sugimoto M
Int J Clin Oncol; 2024 May; 29(5):602-611. PubMed ID: 38418804
[TBL] [Abstract][Full Text] [Related]
20. A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval.
Zameer U; Shaikh W
Tumori; 2023 Dec; ():3008916231221508. PubMed ID: 38142292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
